Literature DB >> 17584748

Coming soon to your clinic: patient-friendly ART.

Guido Pennings1, Willem Ombelet.   

Abstract

The current practice in medically assisted reproduction is still too exclusively focused on effectiveness and success rates. This has a number of considerable, and more importantly, avoidable drawbacks. Single embryo transfer was an important move away from this model to include safety and welfare of mother and child. Patient-friendly ART goes one big step further. It is composed of a mix of four criteria: cost-effectiveness, equity of access, minimal risk for mother and child and minimal burden for patients. All four components have a strong normative ethical basis: cost-effectiveness relies on the optimal use of community resources to maximise well-being; equity of access is based on justice, minimal risk is founded on the fundamental non-maleficence rule and minimal burden is largely based on the autonomy principle. The inclusion of the four criteria in decision-making about treatment would express these values in clinical practice.

Entities:  

Mesh:

Year:  2007        PMID: 17584748     DOI: 10.1093/humrep/dem158

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  10 in total

1.  Why more is less and less is more when it comes to ovarian stimulation.

Authors:  Zeev Blumenfeld
Journal:  J Assist Reprod Genet       Date:  2015-10-19       Impact factor: 3.412

2.  Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy.

Authors:  Svetoslav Stoev; Ilko Getov; Tanya Timeva; Emilia K Naseva; Hristina Lebanova; Boyka Petkova
Journal:  Eur J Hosp Pharm       Date:  2019-05-04

3.  Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patients.

Authors:  E Scott Sills; Gary S Collins; Shala A Salem; Christopher A Jones; Alison C Peck; Rifaat D Salem
Journal:  Reprod Biol Endocrinol       Date:  2012-08-30       Impact factor: 5.211

4.  High-response intrauterine insemination cycles converted to low-cost in vitro fertilization.

Authors:  Fatma Aletebi
Journal:  J Multidiscip Healthc       Date:  2011-05-10

5.  Low dose of rFSH [100 IU] in controlled ovarian hyperstimulation response: a pilot study.

Authors:  Caio Parente Barbosa; Emerson Barchi Cordts; Andrea Couto Costa; Renato de Oliveira; Marina Acosta de Mendonça; Denise Maria Christofolini; Bianca Bianco
Journal:  J Ovarian Res       Date:  2014-01-21       Impact factor: 4.234

6.  Impaired semen quality in trans women: prevalence and determinants.

Authors:  I de Nie; A Meißner; E H Kostelijk; A T Soufan; I A C Voorn-de Warem; M den Heijer; J Huirne; N M van Mello
Journal:  Hum Reprod       Date:  2020-07-01       Impact factor: 6.918

7.  Observational retrospective study of US national utilisation patterns and live birth rates for various ovarian stimulation protocols for in vitro fertilisation.

Authors:  Vitaly A Kushnir; Sarah K Darmon; David H Barad; Norbert Gleicher
Journal:  BMJ Open       Date:  2018-11-08       Impact factor: 2.692

8.  Reproductive outcomes of vitrified blastocyst transfer in modified natural cycle versus mild hormonally stimulated and artificial protocols: A randomized control trial.

Authors:  Otoufe Sheikhi; Masoumeh Golsorkhtabaramiri; Sedighe Esmaeilzadeh; Treza Mahouti; Fateme Nadi Heidari
Journal:  JBRA Assist Reprod       Date:  2018-09-01

9.  A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol.

Authors:  P Devroey; R Boostanfar; N P Koper; B M J L Mannaerts; P C Ijzerman-Boon; B C J M Fauser
Journal:  Hum Reprod       Date:  2009-08-14       Impact factor: 6.918

10.  Comparison of results of cycles treated with modified mild protocol and short protocol for ovarian stimulation.

Authors:  F Coelho; L F Aguiar; G S P Cunha; N Cardinot; E Lucena
Journal:  Int J Reprod Med       Date:  2014-08-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.